Harbour BioMed Receives Chinese Approval to Study New Cancer Drug
Harbour BioMed has received approval from China's National Medical Products Administration (NMPA) to proceed with clinical trials for HBM7004, a drug candidate for advanced solid tumors.
Harbour BioMed announced it has received approval from China's National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application for HBM7004. This approval allows the company to initiate clinical studies of the drug candidate in China for the treatment of advanced solid tumors.
The company previously announced a similar IND approval from the U.S. Food and Drug Administration (FDA) for HBM7004. The dual approvals signify progress in the drug's development pathway in key global markets.
HBM7004 is a novel bispecific antibody designed to target two distinct tumor-associated antigens, potentially offering a new therapeutic approach for patients with limited treatment options. Harbour BioMed is developing the drug candidate with the aim of improving treatment outcomes.
The biopharmaceutical company focuses on the discovery and development of antibody therapeutics for oncology and immunology indications. Harbour BioMed is listed on the Hong Kong Stock Exchange (HKEX: 02142).